Jaz­z's re­worked nar­colep­sy drug wins 7 years of or­phan ex­clu­siv­i­ty thanks to rare 'clin­i­cal su­pe­ri­or­i­ty' find­ing from FDA

Jazz Phar­ma­ceu­ti­cals suc­cess­ful­ly re­designed its block­buster nar­colep­sy drug Xyrem to make it safer by great­ly re­duc­ing its sodi­um con­tent. That tweak was enough for Jazz …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER